These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. An ocular bioavailability comparison in rabbits of prednisolone acetate after repeated topical applications formulated as a high-viscosity gel and as an aqueous suspension. Johansen S; Rask-Pedersen E; Prause JU Acta Ophthalmol Scand; 1996 Jun; 74(3):259-64. PubMed ID: 8828723 [TBL] [Abstract][Full Text] [Related]
23. Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility. Mou D; Chen H; Wan J; Xu H; Yang X Int J Pharm; 2011 Jul; 413(1-2):237-44. PubMed ID: 21540090 [TBL] [Abstract][Full Text] [Related]
24. A bioavailability comparison in rabbits after a single topical ocular application of prednisolone acetate formulated as a high-viscosity gel and as an aqueous suspension. Johansen S; Rask-Pedersen E; Prause JU Acta Ophthalmol Scand; 1996 Jun; 74(3):253-8. PubMed ID: 8828722 [TBL] [Abstract][Full Text] [Related]
25. Endotracheal Aerosolization Device for Laboratory Investigation of Pulmonary Delivery of Nanoparticle Suspensions: In Vitro and in Vivo Validation. Huang Z; Huang Y; Ma C; Ma X; Zhang X; Lin L; Zhao Z; Pan X; Wu C Mol Pharm; 2018 Dec; 15(12):5521-5533. PubMed ID: 30252486 [TBL] [Abstract][Full Text] [Related]
26. Production and characterization of a budesonide nanosuspension for pulmonary administration. Jacobs C; Müller RH Pharm Res; 2002 Feb; 19(2):189-94. PubMed ID: 11883646 [TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD. Dunn LJ; Kerwin EM; DeAngelis K; Darken P; Gillen M; Dorinsky P Pulm Pharmacol Ther; 2020 Feb; 60():101873. PubMed ID: 31841699 [TBL] [Abstract][Full Text] [Related]
28. [Effect of Methylcellulose (Cellulose Derivatives) on Ibuprofen-crushing Efficiency in Nano Pulverizer NP-100]. Nagai N; Yamasaki Y; Nakamura T; Otake H; Okamoto N Yakugaku Zasshi; 2019; 139(1):123-130. PubMed ID: 30606918 [TBL] [Abstract][Full Text] [Related]
29. Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: pharmacokinetics and pharmacodyanamic study. Gora S; Mustafa G; Sahni JK; Ali J; Baboota S Drug Deliv; 2016; 23(3):940-50. PubMed ID: 24937379 [TBL] [Abstract][Full Text] [Related]
30. Levodopa-carbidopa intestinal gel high concentration formulation is clinically bioequivalent to commercial formulation. Rosebraugh M; Kalluri HV; Liu W; Locke C; Sidhu D; Han JH; Benesh J Pharmacol Res Perspect; 2019 Apr; 7(2):e00473. PubMed ID: 30977301 [TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic study for the establishment of bioequivalence of two inhalation treatments containing budesonide plus formoterol. Grekas N; Athanassiou K; Papataxiarchou K; Rizea Savu S; Silvestro L J Pharm Pharmacol; 2014 Dec; 66(12):1677-85. PubMed ID: 25109416 [TBL] [Abstract][Full Text] [Related]
32. Preparation of multiparticulate systems for oral delivery of a micronized or nanosized poorly soluble drug. Cerea M; Pattarino F; Foglio Bonda A; Palugan L; Segale L; Vecchio C Drug Dev Ind Pharm; 2016 Sep; 42(9):1466-75. PubMed ID: 26786555 [TBL] [Abstract][Full Text] [Related]
33. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions. Chen C; Bujanover S; Kareht S; Rapoport AM Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369 [TBL] [Abstract][Full Text] [Related]
34. Cyclosporine A Nanosuspensions for Ophthalmic Delivery: A Comparative Study between Cationic Nanoparticles and Drug-Core Mucus Penetrating Nanoparticles. Yan R; Xu L; Wang Q; Wu Z; Zhang H; Gan L Mol Pharm; 2021 Dec; 18(12):4290-4298. PubMed ID: 34731571 [TBL] [Abstract][Full Text] [Related]
35. Pulmonary targeting of sustained release formulation of budesonide in neonatal rats. Arya V; Coowanitwong I; Brugos B; Kim WS; Singh R; Hochhaus G J Drug Target; 2006 Dec; 14(10):680-6. PubMed ID: 17162737 [TBL] [Abstract][Full Text] [Related]
36. Nanosuspensions Containing Oridonin/HP-β-Cyclodextrin Inclusion Complexes for Oral Bioavailability Enhancement via Improved Dissolution and Permeability. Zhang X; Zhang T; Lan Y; Wu B; Shi Z AAPS PharmSciTech; 2016 Apr; 17(2):400-8. PubMed ID: 26187778 [TBL] [Abstract][Full Text] [Related]
37. Nanoparticle-Based Topical Ophthalmic Gel Formulation for Sustained Release of Hydrocortisone Butyrate. Yang X; Trinh HM; Agrahari V; Sheng Y; Pal D; Mitra AK AAPS PharmSciTech; 2016 Apr; 17(2):294-306. PubMed ID: 26085051 [TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo Evaluation of Ibuprofen Nanosuspensions for Enhanced Oral Bioavailability. Hedaya M; Bandarkar F; Nada A Med Princ Pract; 2021; 30(4):361-368. PubMed ID: 33823524 [TBL] [Abstract][Full Text] [Related]
39. Formulation and Evaluation of Naringenin Nanosuspensions for Bioavailability Enhancement. Gera S; Talluri S; Rangaraj N; Sampathi S AAPS PharmSciTech; 2017 Nov; 18(8):3151-3162. PubMed ID: 28534300 [TBL] [Abstract][Full Text] [Related]